Harvest One Cannabis Inc. (TSXV:HVT, OTCQX:HRVOF) subsidiary Satipharm AG spoke about the proprietary Gelpell® technology.
Harvest One Cannabis Inc. (TSXV:HVT, OTCQX:HRVOF) subsidiary Satipharm AG spoke about the proprietary Gelpell® technology during the Dublin Marathon Expo in Dublin, Ireland. Satipharm AG is a health and well-being company that specializes in the development and manufacturing of cannabinoid-based products.
Gelpell® technology is designed to help address the bioavailability and consistency issues associated with the delivery of orally-ingested cannabis-based products. Satipharm has completed clinical trials on the Gelpell® capsules with PhytoTech Therapeutics Limited (PTL). Satipharm representative Matthew Gavin talked about CBD capsules and Gelpell® technology, and said, “it makes it 360 percent more effective than oils, so our phase one and phase two clinical trials showed us data that we can place cannabinoids into micro-gelatin spheres.”
Click here to watch the full video.